Poster

SARS-CoV-2 infection and long COVID

P 112
SARS-CoV-2 natural infection, but not vaccine-induced immunity, elicits cross-reactive immunity to OC43

P 113
Use of combination therapy with remdesivir, nirmatrelvir/ritonavir and sotrovimab in an immunocompromised patient with persistent severe SARS-CoV-2 acute respiratory syndrome

P 114
Exploring Early COVID-19 Therapies, Variants, and Viral Clearance Dynamics: Insights from a High-Risk Outpatients Study

P 115
Characteristics of Long COVID after two years of follow-up in a previously hospitalized population

P 116
The evolving landscape of COVID-19: Characteristics and factors associated with disease severity and mortality in recent hospitalisations

P 117
Prolonged combination treatment: an efficient and safe strategy for managing SARS-CoV-2 infection in immunocompromised patients

P 118
Cytomegalovirus reactivation in non-severe COVID-19: two emblematic cases of oropharyngeal mucositis in immunocompromised patients

P 119
Combination therapy in immunocompromised patients with COVID-19

P 120
Sex disparity in COVID infection: a retrospective study using serum electrophoretic analysis (SPE) in men and women infected by COVID-19

×

Commento audio

Chiudi